中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢加急性肝衰竭的免疫治疗

覃小宾 张荣臻 吴聪 曾胜澜 乐滢玉 毛德文

覃小宾,张荣臻,吴聪,等. 慢加急性肝衰竭的免疫治疗[J]. 临床肝胆病杂志, 2021, 37(11): 2696-2700. DOI: 10.3969/j.issn.1001-5256.2021.11.046.
引用本文: 覃小宾,张荣臻,吴聪,等. 慢加急性肝衰竭的免疫治疗[J]. 临床肝胆病杂志, 2021, 37(11): 2696-2700. DOI: 10.3969/j.issn.1001-5256.2021.11.046.
QIN XB, ZHANG RZ, WU C, et al. Immunotherapy for acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(11): 2696-2700. DOI: 10.3969/j.issn.1001-5256.2021.11.046.
Citation: QIN XB, ZHANG RZ, WU C, et al. Immunotherapy for acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(11): 2696-2700. DOI: 10.3969/j.issn.1001-5256.2021.11.046.

慢加急性肝衰竭的免疫治疗

DOI: 10.3969/j.issn.1001-5256.2021.11.046
基金项目: 

国家自然科学基金 81960841;

国家自然科学基金面上项目 82060848;

广西自然科学基金课题 2018GXNSFAA281096;

广西自然科学基金课题 2020JJA140273

详细信息
    通信作者:

    毛德文,mdwboshi2005@163.com

  • 中图分类号: R575.3

Immunotherapy for acute-on-chronic liver failure

Research funding: 

National Natural Science Foundation Project 81960841;

General Project of National Natural Science Foundation Project 82060848;

Guangxi Natural Science Fund Project 2018GXNSFAA281096;

Guangxi Natural Science Fund Project 2020JJA140273

  • 摘要: 慢加急性肝衰竭(ACLF)是一种严重威胁生命的疾病,具有多器官衰竭、脓毒症和死亡的高风险。ACLF在体内激活先天免疫反应和获得性免疫反应,从而引起持续的全身炎症反应综合征和多器官功能障碍的发展,导致该病的高病死率。失调的免疫反应在疾病进展中起关键作用,免疫疗法可能有助于针对免疫介导的器官损伤,抑制肝衰竭的进展,就目前ACLF中具有潜在免疫调节作用的药物与手段的作用及其机制进行了综述,以期为ACLF的免疫治疗提供参考。

     

  • [1] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [2] YIN S, WANG SJ, GU WY, et al. Risk of different precipitating events for progressing to acute-on-chronic liver failure in HBV-related cirrhotic patients[J]. J Dig Dis, 2017, 18(5): 292-301. DOI: 10.1111/1751-2980.12480.
    [3] SATSANGI S, DUSEJA A, SACHDEVA M, et al. Monocyte human leukocyte antigen - Antigen D related, neutrophil oxidative burst and cytokine analysis in patients of decompensated cirrhosis with and without acute-on chronic liver failure[J]. PLoS One, 2018, 13(7): e0200644. DOI: 10.1371/journal.pone.0200644.
    [4] CHEN P, WANG YY, CHEN C, et al. The immunological roles in acute-on-chronic liver failure: An update[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(5): 403-411. DOI: 10.1016/j.hbpd.2019.07.003.
    [5] SHUBHAM S, KUMAR D, ROOGE S, et al. Cellular and functional loss of liver endothelial cells correlates with poor hepatocyte regeneration in acute-on-chronic liver failure[J]. Hepatol Int, 2019, 13(6): 777-787. DOI: 10.1007/s12072-019-09983-y.
    [6] MA HC, SHI XL, REN HZ, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 to acute failing liver improves liver regeneration[J]. World J Gastroenterol, 2014, 20(40): 14884-14894. DOI: 10.3748/wjg.v20.i40.14884.
    [7] LEI Y, LIU Z, HAN Q, et al. G-CSF enhanced SDF-1 gradient between bone marrow and liver associated with mobilization of peripheral blood CD34+ cells in rats with acute liver failure[J]. Dig Dis Sci, 2010, 55(2): 285-291. DOI: 10.1007/s10620-009-0757-9.
    [8] KHANAM A, TREHANPATI N, GARG V, et al. Altered frequencies of dendritic cells and IFN-gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on- chronic liver failure[J]. Liver Int, 2014, 34(4): 505-513. DOI: 10.1111/liv.12415.
    [9] SHARMA S, LAL SB, SACHDEVA M, et al. Role of granulocyte colony stimulating factor on the short-term outcome of children with acute on chronic liver failure[J]. J Clin Exp Hepatol, 2020, 10(3): 201-210. DOI: 10.1016/j.jceh.2019.10.001.
    [10] KARIMINEKOO S, MOVASSAGHPOUR A, RAHIMZADEH A, et al. Implications of mesenchymal stem cells in regenerative medicine[J]. Artif Cells Nanomed Biotechnol, 2016, 44(3): 749-757. DOI: 10.3109/21691401.2015.1129620.
    [11] LIN BL, CHEN JF, QIU WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial[J]. Hepatology, 2017, 66(1): 209-219. DOI: 10.1002/hep.29189.
    [12] MOUNAYAR M, KEFALOYIANNI E, SMITH B, et al. PI3kα and STAT1 interplay regulates human mesenchymal stem cell immune polarization[J]. Stem Cells, 2015, 33(6): 1892-1901. DOI: 10.1002/stem.1986.
    [13] JITSCHIN R, BÖTTCHER M, SAUL D, et al. Inflammation-induced glycolytic switch controls suppressivity of mesenchymal stem cells via STAT1 glycosylation[J]. Leukemia, 2019, 33(7): 1783-1796. DOI: 10.1038/s41375-018-0376-6.
    [14] LIEDER R, SIGURJONSSON OE. The effect of recombinant human interleukin-6 on osteogenic differentiation and YKL-40 expression in human, bone marrow-derived mesenchymal stem cells[J]. Biores Open Access, 2014, 3(1): 29-34. DOI: 10.1089/biores.2013.0035.
    [15] LIU Q, CHEN X, LIU C, et al. Mesenchymal stem cells alleviate experimental immune-mediated liver injury via chitinase 3-like protein 1-mediated T cell suppression[J]. Cell Death Dis, 2021, 12(3): 240. DOI: 10.1038/s41419-021-03524-y.
    [16] NEONG SF, ADEBAYO D, WONG F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 293-305. DOI: 10.1080/17474124.2018.1555469.
    [17] ARNAU-BARRÉS I, GVERRI-FERNÁNDEZ R, LUQUE S, et al. Serum albumin is a strong predictor of sepsis outcome in elderly patients[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(4): 743-746. DOI: 10.1007/s10096-019-03478-2.
    [18] O'Brien AJ, BRIEN AJ, FULLERTON JN, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2[J]. Nat Med, 2014, 20(5): 518-523. DOI: 10.1038/nm.3516.
    [19] CARACENI P, PAVESI M, BALDASSARRE M, et al. The use of human albumin in patients with cirrhosis: A European survey[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(6): 625-632. DOI: 10.1080/17474124.2018.1460203.
    [20] GIANNONE FA, DOMENICALI M, BALDASSARRE M, et al. Ischaemia-modified albumin: A marker of bacterial infection in hospitalized patients with cirrhosis[J]. Liver Int, 2015, 35(11): 2425-2432. DOI: 10.1111/liv.12860.
    [21] KUMAR PA, SUBRAMANIAN K. The role of ischemia modified albumin as a biomarker in patients with chronic liver disease[J]. J Clin Diagn Res, 2016, 10(3): BC09-12. DOI: 10.7860/JCDR/2016/17168.7399.
    [22] GAO L, WANG JF, XIANG M, et al. Expression of human glucocorticoid receptor in T lymphocytes in acute-on-chronic hepatitis B liver failure[J]. Dig Dis Sci, 2011, 56(9): 2605-2612. DOI: 10.1007/s10620-011-1656-4.
    [23] SHIMBA A, CUI G, TANI-ICHI S, et al. Glucocorticoids drive diurnal oscillations in T cell distribution and responses by inducing interleukin-7 receptor and CXCR4[J]. Immunity, 2018, 48(2): 286-298. e6. DOI: 10.1016/j.immuni.2018.01.004.
    [24] YU X, LAN P, HOU X, et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production[J]. J Hepatol, 2017, 66(4): 693-702. DOI: 10.1016/j.jhep.2016.12.018.
    [25] ZHAO Q, WU CS, FANG Y, et al. Glucocorticoid regulates NLRP3 in acute-on-chronic hepatitis B liver failure[J]. Int J Med Sci, 2019, 16(3): 461-469. DOI: 10.7150/ijms.30424.
    [26] ZHE-BIN W, KE W, MO ZS, et al. Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure[J]. Clin Res Hepatol Gastroenterol, 2020 : 101505. DOI: 10.1016/j.clinre.2020.07.010.[Onlineaheadofprint]
    [27] HUANG C, YU KK, ZHENG JM, et al. Steroid treatment in patients with acute-on-chronic liver failure precipitated by hepatitis B: A 10-year cohort study in a university hospital in East China[J]. J Dig Dis, 2019, 20(1): 38-44. DOI: 10.1111/1751-2980.12691.
    [28] THURSZ MR, RICHARDSON P, ALLISON M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis[J]. N Engl J Med, 2015, 372(17): 1619-1628. DOI: 10.1056/NEJMoa1412278.
    [29] TAUBERT R, HARDTKE-WOLENSKI M, NOYAN F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies[J]. J Hepatol, 2014, 61(5): 1106-1114. DOI: 10.1016/j.jhep.2014.05.034.
    [30] OO YH, WESTON CJ, LALOR PF, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver[J]. J Immunol, 2010, 184(6): 2886-2898. DOI: 10.4049/jimmunol.0901216.
    [31] FU XQ, CAI JY, LI MJ. Prednisone may rebuild the immunologic homeostasis: Alteration of Th17 and Treg cells in the lymphocytes from rats' spleens after treated with prednisone-containing serum[J]. Mol Genet Genomic Med, 2019, 7(7): e00800. DOI: 10.1002/mgg3.800.
    [32] KARKHANIS J, VERNA EC, CHANG MS, et al. Steroid use in acute liver failure[J]. Hepatology, 2014, 59(2): 612-621. DOI: 10.1002/hep.26678.
    [33] CHI JH, SEO GS, LEE SH. Oregonin inhibits inflammation and protects against barrier disruption in intestinal epithelial cells[J]. Int Immunopharmacol, 2018, 59: 134-140. DOI: 10.1016/j.intimp.2018.04.006.
    [34] SHAO C, TIAN G, HUANG Y, et al. Thymosin alpha-1-transformed bifidobacterium promotes T cell proliferation and maturation in mice by oral administration[J]. Int Immunopharmacol, 2013, 15(3): 646-653. DOI: 10.1016/j.intimp.2012.12.031.
    [35] SUGAHARA S, ICHIDA T, YAMAGIWA S, et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B[J]. Hepatol Res, 2002, 24(4): 346-354. DOI: 10.1016/s1386-6346(02)00145-6.
    [36] BOZZA S, GAZIANO R, BONIFAZI P, et al. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo[J]. Int Immunol, 2007, 19(11): 1261-1270. DOI: 10.1093/intimm/dxm097.
    [37] YAO Q, DOAN LX, ZHANG R, et al. Thymosin-alpha1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes[J]. Immunol Lett, 2007, 110(2): 110-120. DOI: 10.1016/j.imlet.2007.04.007.
    [38] GARACI E, PICA F, SERAFINO A, et al. Thymosin α1 and cancer: Action on immune effector and tumor target cells[J]. Ann N Y Acad Sci, 2012, 1269: 26-33. DOI: 10.1111/j.1749-6632.2012.06697.x.
    [39] NAYLOR PH, MUTCHNICK MG. Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach[J]. J Viral Hepat, 2018, 25(1): 4-9. DOI: 10.1111/jvh.12807.
    [40] PENG D, XING HY, LI C, et al. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: A systematic review and meta-analysis[J]. BMC Gastroenterol, 2020, 20(1): 348. DOI: 10.1186/s12876-020-01477-8.
    [41] WU J, ZHOU L, LIU J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): A multicenter, single-blind, randomized and controlled trial[J]. Crit Care, 2013, 17(1): R8. DOI: 10.1186/cc11932.
    [42] SARIN SK, CHOUDHURY A. Acute-on-chronic liver failure: terminology, mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(3): 131-149. DOI: 10.1038/nrgastro.2015.219.
    [43] YANG L, WU T, LI J, et al. Artificial liver treatment improves survival in patients with hepatitis B virus-related acute-on-chronic liver failure: A case-control matched analysis[J]. Hepatol Res, 2020, 50(6): 656-670. DOI: 10.1111/hepr.13497.
    [44] LARSEN FS, SCHMIDT LE, BERNSMEIER C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial[J]. J Hepatol, 2016, 64(1): 69-78. DOI: 10.1016/j.jhep.2015.08.018.
    [45] OCSKAY K, KANJO A, GEDE N, et al. Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: A systematic review and network meta-analysis[J]. Ann Intensive Care, 2021, 11(1): 10. DOI: 10.1186/s13613-020-00795-0.
    [46] KHAMRI W, ABELES RD, HOU TZ, et al. Increased expression of cytotoxic T-lymphocyte-associated protein 4 by T cells, induced by B7 in sera, reduces adaptive immunity in patients with acute liver failure[J]. Gastroenterology, 2017, 153(1): 263-276. e8. DOI: 10.1053/j.gastro.2017.03.023.
    [47] ZHANG Z, ZHAO YC, CHENG Y, et al. Hybrid bioartificial liver support in cynomolgus monkeys with D-galactosamine-induced acute liver failure[J]. World J Gastroenterol, 2014, 20(46): 17399-17406. DOI: 10.3748/wjg.v20.i46.17399.
    [48] BAÑARES R, NEVENS F, LARSEN FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial[J]. Hepatology, 2013, 57(3): 1153-1162. DOI: 10.1002/hep.26185.
    [49] KRIBBEN A, GERKEN G, HAAG S, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure[J]. Gastroenterology, 2012, 142(4): 782-789. e3. DOI: 10.1053/j.gastro.2011.12.056.
  • 加载中
计量
  • 文章访问数:  176
  • HTML全文浏览量:  65
  • PDF下载量:  44
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-03-28
  • 录用日期:  2021-04-21
  • 出版日期:  2021-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回